在纤维化中出现的表观遗传修饰:从机制到治疗方法
Xiaoguo Suo1, Qinglin Ge1, Lijin Peng1
1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmaceutical Sciences, Anhui Medical University, Hefei 230032, China.
Acta pharmaceutica Sinica. B
|January 1, 2026
概括
表观遗传修饰是慢性病 (CKD) 中纤维化的主要驱动因素. 针对这些表观遗传变化,有望开发新的抗纤维菌疗法来治疗病.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 慢性病 (CKD) 是一个日益严重的全球健康问题,发病率和死亡率不断增加.
- 纤维化是CKD进展到末期病的主要驱动因素.
- 目前对纤维化的治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 审查纤维化的表观遗传修饰的调节网络.
- 探索表观遗传修饰药物作为抗纤维菌剂的潜力.
- 讨论对CKD的表观遗传研究当前的挑战和未来的机会.
主要方法:
- 在纤维化中的表观遗传机制的文献综述和分析.
- 检查纤维化脏模型中表观遗传修饰药物的研究.
- 综合发现,提供对分子机制和治疗开发的见解.
主要成果:
- 表观遗传修饰在纤维化病变发生过程中起着重要作用.
- 在临床前模型中,表观遗传向药物已经显示出有前途的抗纤维菌作用.
- 了解这些表观遗传网络为CKD治疗提供了新的途径.
结论:
- 表观遗传修饰在纤维化中至关重要,并代表了可行的治疗点.
- 对表观遗传调节的进一步研究可能会导致CKD的新型抗纤维菌疗法.
- 向表观遗传途径具有预防和治疗纤维化的巨大潜力.
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
319
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
319
Acute Kidney Injury II: Pathophysiology
840
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
840
Acute Kidney Injury I: Introduction
511
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
511
Acute Kidney Injury III: Clinical Manifestations
763
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
763
Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
166
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
166


